Impact of Viral Dose and Major Histocompatibility Complex Class IB Haplotype on Viral Outcome in Mauritian Cynomolgus Monkeys Vaccinated with Tat upon Challenge with Simian/Human Immunodeficiency Virus SHIV89.6P
-
Published:2010-09
Issue:17
Volume:84
Page:8953-8958
-
ISSN:0022-538X
-
Container-title:Journal of Virology
-
language:en
-
Short-container-title:J Virol
Author:
Cafaro Aurelio1, Bellino Stefania1, Titti Fausto1, Maggiorella Maria Teresa1, Sernicola Leonardo1, Wiseman Roger W.2, Venzon David3, Karl Julie A.2, O'Connor David2, Monini Paolo1, Robert-Guroff Marjorie4, Ensoli Barbara1
Affiliation:
1. National AIDS Center, Istituto Superiore di Sanità, Rome, Italy 2. Wisconsin National Primate Research Center and Department of Pathology and Laboratory Medicine, University of Wisconsin—Madison, Madison, Wisconsin 3. Biostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 4. Vaccine Branch and National Cancer Institute, National Institutes of Health, Bethesda, Maryland
Abstract
ABSTRACT
The effects of the challenge dose and major histocompatibility complex (MHC) class IB alleles were analyzed in 112 Mauritian cynomolgus monkeys vaccinated (
n
= 67) or not vaccinated (
n
= 45) with Tat and challenged with simian/human immunodeficiency virus (SHIV) 89.6P
cy243.
In the controls, the challenge dose (10 to 20 50% monkey infectious doses [MID
50
]) or MHC did not affect susceptibility to infection, peak viral load, or acute CD4 T-cell loss, whereas in the chronic phase of infection, the H1 haplotype correlated with a high viral load (
P
= 0.0280) and CD4 loss (
P
= 0.0343). Vaccination reduced the rate of infection acquisition at 10 MID
50
(
P
< 0.0001), and contained acute CD4 loss at 15 MID
50
(
P
= 0.0099). Haplotypes H2 and H6 were correlated with increased susceptibility (
P
= 0.0199) and resistance (
P
= 0.0087) to infection, respectively. Vaccination also contained CD4 depletion (
P
= 0.0391) during chronic infection, independently of the challenge dose or haplotype.
Publisher
American Society for Microbiology
Subject
Virology,Insect Science,Immunology,Microbiology
Reference28 articles.
1. Anastassopoulou, C. G., and L. G. Kostrikis. 2003. The impact of human allelic variation on HIV-1 disease. Curr. HIV Res.1:185-203. 2. Bellino, S., V. Francavilla, O. Longo, A. Tripiciano, G. Paniccia, A. Arancio, V. Fiorelli, A. Scoglio, B. Collacchi, M. Campagna, A. Lazzarin, G. Tambussi, C. T. Din, R. Visintini, P. Narciso, A. Antinori, G. D'Offizi, M. Giulianelli, M. Carta, A. Di Carlo, G. Palamara, M. Giuliani, M. E. Laguardia, P. Monini, M. Magnani, F. Ensoli, and B. Ensoli. 2009. Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate. Rev. Recent Clin. Trials4:195-204. 3. Borsetti, A., S. Baroncelli, M. T. Maggiorella, S. Bellino, S. Moretti, L. Sernicola, R. Belli, B. Ridolfi, S. Farcomeni, D. R. Negri, A. Cafaro, B. Ensoli, and F. Titti. 2008. Viral outcome of simian-human immunodeficiency virus SHIV-89.6P adapted to cynomolgus monkeys. Arch. Virol.153:463-472. 4. Cafaro, A., A. Caputo, C. Fracasso, M. T. Maggiorella, D. Goletti, S. Baroncelli, M. Pace, L. Sernicola, M. L. Koanga-Mogtomo, M. Betti, A. Borsetti, R. Belli, L. Akerblom, F. Corrias, S. Butto, J. Heeney, P. Verani, F. Titti, and B. Ensoli. 1999. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat. Med.5:643-650. 5. Cafaro, A., A. Caputo, M. T. Maggiorella, S. Baroncelli, C. Fracasso, M. Pace, A. Borsetti, L. Sernicola, D. R. Negri, P. ten Haaft, M. Betti, Z. Michelini, I. Macchia, E. Fanales-Belasio, R. Belli, F. Corrias, S. Butto, P. Verani, F. Titti, and B. Ensoli. 2000. SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine. J. Med. Primatol.29:193-208.
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|